|Differences in rSBA vaccine response rate between the ACWY-TT and the Men-PS groups|
|Antibody||ACWY-TT||Men-PS||Difference in vaccine response rate (ACWY-TT minus Men-PS)|
|N||%||N||%||% [95% CI]|
|rSBA-MenA||289||82.7||99||69.7||13.00 [3.52, 23.50]|
|rSBA-MenC||324||94.4||113||90.3||4.18 [−1.03, 11.36]|
|rSBA-MenW-135||326||96.3||109||91.7||4.58 [−0.07, 11.49]|
|rSBA-MenY||329||93.0||113||85.0||8.05 [1.72, 16.17]|
ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
Vaccine response defined as:
• rSBA titre ≥32 at Month 1 for initially seronegative participants (rSBA titre <8).
• rSBA titre at Month 1 ≥4-fold the antibody titre at Month 0 for initially seropositive participants (rSBA titre ≥8).
N = number of participants with pre- and post-vaccination results available (ATP immunogenicity cohort).
% = percentage of participants with a vaccine response.
95% CI = standardised asymptotic 95% confidence interval.
Bold = lower limits of the 95% confidence intervals of the differences in vaccine response rates, which were used to demonstrate non-inferiority.
Borja-Tabora et al.
Borja-Tabora et al. BMC Infectious Diseases 2013 13:116 doi:10.1186/1471-2334-13-116